The favorable short-term outcomes observed in the national cohort may be explained by the protective effect of biologic therapies commonly used in IBD, such as anti-TNF agents, which may alleviate acute myocardial inflammation during hospitalization while not fully eliminating long-term susceptibility. This evidence concerns the gene TNF and inflammatory bowel disease.